HU1000069D0 - New salts for the preparation of pharmaceutical composition - Google Patents

New salts for the preparation of pharmaceutical composition

Info

Publication number
HU1000069D0
HU1000069D0 HU1000069A HUP1000069A HU1000069D0 HU 1000069 D0 HU1000069 D0 HU 1000069D0 HU 1000069 A HU1000069 A HU 1000069A HU P1000069 A HUP1000069 A HU P1000069A HU 1000069 D0 HU1000069 D0 HU 1000069D0
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical composition
new salts
salts
new
Prior art date
Application number
HU1000069A
Other languages
English (en)
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Priority to HU1000069A priority Critical patent/HUP1000069A2/hu
Publication of HU1000069D0 publication Critical patent/HU1000069D0/hu
Priority to PCT/HU2011/000014 priority patent/WO2011110876A1/en
Priority to EA201290726A priority patent/EA022496B1/ru
Priority to CN2011800153251A priority patent/CN102858762A/zh
Publication of HUP1000069A2 publication Critical patent/HUP1000069A2/hu
Priority to ZA2012/06254A priority patent/ZA201206254B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU1000069A 2010-02-02 2010-02-02 New salts for the preparation of pharmaceutical composition HUP1000069A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HU1000069A HUP1000069A2 (en) 2010-02-02 2010-02-02 New salts for the preparation of pharmaceutical composition
PCT/HU2011/000014 WO2011110876A1 (en) 2010-02-02 2011-02-02 Novel salts for the manufacture of pharmaceutical compositions
EA201290726A EA022496B1 (ru) 2010-02-02 2011-02-02 Полиморфная форма гидрохлорида дабигатрана этексилата
CN2011800153251A CN102858762A (zh) 2010-02-02 2011-02-02 用于制备药物组合物的新的盐
ZA2012/06254A ZA201206254B (en) 2010-02-02 2012-08-20 Novel salts for the manufacture of pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1000069A HUP1000069A2 (en) 2010-02-02 2010-02-02 New salts for the preparation of pharmaceutical composition

Publications (2)

Publication Number Publication Date
HU1000069D0 true HU1000069D0 (en) 2010-04-28
HUP1000069A2 HUP1000069A2 (en) 2012-05-02

Family

ID=89989543

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1000069A HUP1000069A2 (en) 2010-02-02 2010-02-02 New salts for the preparation of pharmaceutical composition

Country Status (5)

Country Link
CN (1) CN102858762A (hu)
EA (1) EA022496B1 (hu)
HU (1) HUP1000069A2 (hu)
WO (1) WO2011110876A1 (hu)
ZA (1) ZA201206254B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2012027543A1 (en) * 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) * 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
CN102633777B (zh) * 2012-03-31 2014-04-16 天津药物研究院 达比加群酯2-酮戊二酸盐及其制备方法和应用
EP2834224B1 (en) 2012-04-02 2018-06-06 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
JP2015522596A (ja) * 2012-07-16 2015-08-06 インテルキム、ソシエダッド アノニマ ダビガトランエテキシラートの合成のための中間体を調製する方法及び該中間体の結晶形
WO2014049586A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
IN2015DN02616A (hu) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
CN103864756B (zh) * 2012-12-11 2018-06-15 四川海思科制药有限公司 丁二磺酸达比加群酯及其制备方法和用途
WO2014178017A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418840A (zh) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯无水化合物
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104892574A (zh) * 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
CN104974137A (zh) * 2014-04-04 2015-10-14 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
US20170165247A1 (en) * 2014-07-18 2017-06-15 Olon S.P.A. Crystalline compounds of dabigatran etexilate
CN105348260A (zh) * 2014-08-19 2016-02-24 天津药物研究院 达比加群酯氢溴酸盐及其制备方法和应用
CN106554370A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 含有磷酸酯的达比加群衍生物及其制备方法和用途
CN116621815A (zh) * 2023-07-21 2023-08-22 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯的工业化制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
WO2008009638A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
CN100556642C (zh) * 2007-06-06 2009-11-04 中国科学院化学研究所 脂肪族聚己二酸丁二酯材料降解性能的调控方法

Also Published As

Publication number Publication date
EA022496B1 (ru) 2016-01-29
WO2011110876A1 (en) 2011-09-15
ZA201206254B (en) 2013-10-30
CN102858762A (zh) 2013-01-02
WO2011110876A8 (en) 2012-07-05
HUP1000069A2 (en) 2012-05-02
EA201290726A1 (ru) 2013-07-30

Similar Documents

Publication Publication Date Title
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
HK1246170A1 (zh) 藥物組合物
IL225457A0 (en) Pharmaceutical composition
SI2619182T1 (sl) Farmacevtski sestavek
EP2654736A4 (en) NEW PHARMACEUTICAL COMPOSITION
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
ZA201207375B (en) Stabilized pharmaceutical composition
HRP20160901T1 (hr) Farmaceutski pripravak koji sadrži solifenacin
EP2668852A4 (en) COMPOSITION FOR ORAL ADMINISTRATION
PT2594266E (pt) Composições farmacêuticas sólidas que contêm sais de ibuprofeno
GB201001911D0 (en) Pharmaceutical composition
HK1188959A1 (zh) 磷霉素藥物組合物
ZA201308414B (en) Solid pharmaceutical composition
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
HU1000624D0 (en) Novel salts skitable for the preparation of pharmaceutical compositions
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees